Expand SPRY Menu
SPRY MENU

SPRY Latest Press Releases

-- February 10, 2026 --

ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting Globe Newswire 8:00 AM

-- February 2, 2026 --

EURneffy 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing =15 kg to <30 kg Globe Newswire 8:00 AM

-- January 21, 2026 --

California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use Globe Newswire 8:00 AM

-- December 29, 2025 --

neffy (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) Globe Newswire 8:00 AM

-- November 26, 2025 --

ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference Globe Newswire 8:00 AM

-- November 10, 2025 --

ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy (epinephrine nasal spray) Globe Newswire 6:00 AM

-- November 4, 2025 --

ARS Pharma Launches Get neffy on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray) Globe Newswire 8:00 AM

-- November 3, 2025 --

UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting Globe Newswire 2:23 PM
ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results Globe Newswire 8:00 AM
ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting Globe Newswire 7:45 AM

-- October 8, 2025 --

ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy (epinephrine nasal spray) Globe Newswire 8:00 AM

-- September 29, 2025 --

ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy Globe Newswire 4:05 PM

-- September 19, 2025 --

neffy (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes